Literature DB >> 10800163

Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo.

J M Hernández1, M B González, I Granada, N Gutiérrez, C Chillón, F Ramos, J M Ribera, M González, E Feliu, J San Miguel.   

Abstract

BACKGROUND AND
OBJECTIVE: It has been established that cytogenetic findings at the time of diagnosis of acute myeloid leukemia (AML) are powerful prognostic indicators. Pericentric inversion of chromosome 16 and translocation t(16;16) resulting in chimeric fusion of CBFB and MYH11 genes are typically seen in the M4-Eo FAB classification subset of AML and are associated with low-risk disease. These subtle chromosomal abnormalities may be difficult to detect in poor-quality metaphase preparations and if missed could lead to incorrect assignment to risk groups and influence the therapy decision-making process. DESIGN AND METHODS: We prospectively studied, at diagnosis, 10 patients with AML-M4 Eo by cytogenetics and fluorescent in situ hybridization (FISH) with two cosmids (36 and 40). As a control group, 7 patients (5 with a diagnosis of AML other than M4 Eo and two cases of reactive eosinophilia) were analyzed. In addition reverse transcriptase chain reaction (RT-PCR) studies were carried out in 6 cases.
RESULTS: Karyotypic analysis detected the inv(16) in all but one of the patients with M4-Eo while none of the control cases showed any abnormality on chromosome 16. FISH studies showed that all 10 patients had abnormalities on chromosome 16; the patient with normal karyotype showed an inv(16) by FISH, while a case with inv(16) by cytogenetics had a t(16;16) by FISH. RT-PCR demonstrated amplification of the CBFB/MYH11 product in all cases analyzed. INTERPRETATION AND
CONCLUSIONS: In patients with M4Eo and rearrangements of chromosome 16, FISH studies may afford more complete information than conventional cytogenetics and can be an alternative to RT-PCR studies.

Entities:  

Mesh:

Year:  2000        PMID: 10800163

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  4 in total

1.  Overexpression of the VAV proto-oncogene product is associated with B-cell chronic lymphocytic leukaemia displaying loss on 13q.

Authors:  Rosario M Prieto-Sánchez; José A Hernández; Juan L García; Norma C Gutiérrez; Jesús San Miguel; Xosé R Bustelo; Jesús M Hernández
Journal:  Br J Haematol       Date:  2006-06       Impact factor: 6.998

2.  Fluorescence in situ hybridization identifies cryptic t(16;16)(p13;q22) masked by del(16)(q22) in a case of AML-M4 Eo.

Authors:  Shakil H Merchant; Skip Haines; Bryan Hall; John Hozier; David S Viswanatha
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

3.  Expression of VAV1 in the tumour microenvironment of glioblastoma multiforme.

Authors:  Juan Luis Garcia; Jose Couceiro; Juan Antonio Gomez-Moreta; J M Gonzalez Valero; Angel Santos Briz; Vincent Sauzeau; Eva Lumbreras; Manuel Delgado; Cristina Robledo; Monica Lara Almunia; Xose R Bustelo; Jesus M Hernandez
Journal:  J Neurooncol       Date:  2012-08-04       Impact factor: 4.130

4.  Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy.

Authors:  Andrés E Quesada; Rajyalakshmi Luthra; Elias Jabbour; Keyur P Patel; Joseph D Khoury; Zhenya Tang; Hector Alvarez; Saradhi Mallampati; Guillermo Garcia-Manero; Guillermo Montalban-Bravo; L Jeffrey Medeiros; Rashmi Kanagal-Shamanna
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-06-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.